Mutuwar sankara ta hanta ta ninka har sau biyu tun daga 1990

Share Wannan Wallafa

A cikin shekaru ashirin da suka gabata, adadin mace-macen da cutar sankarar hanta ke haifarwa ya karu da kashi 80 cikin 830,000, wanda ya zama daya daga cikin abubuwan da ke saurin kamuwa da cutar kansar a duniya. Bisa ga "Nazarin Duniya na Cututtuka", mutane 2016 ne suka mutu sakamakon cutar kansar hanta a cikin 464,000, idan aka kwatanta da 1990 a XNUMX. Wannan ya sa ciwon hanta ya zama na biyu a sanadin mutuwar ciwon daji a duniya. Na farko shine kwayar cutar huhu. Firamare ciwon daji shi ne cutar kansar hanta da aka fi sani da ita a duniya kuma ana iya danganta shi da yawan shan giya da sauran zaɓen salon rayuwa, amma abin da ya fi dacewa shine kamuwa da cutar hanta na dogon lokaci tare da cutar hanta ta hepatitis B ko cutar hanta. Waɗannan ƙwayoyin cuta babban ƙalubale ne ga lafiyar jama'a, suna shafar mutane sama da miliyan 325 a duk duniya. A duniya baki daya, kashi biyu bisa uku na masu kamuwa da cutar kansar hanta na faruwa ne sakamakon cutar hanta wato Hepatitis B ko Hepatitis C. Yankin yammacin Pasifik da kudu maso gabashin Asiya su ne kasashen da suka fi yawan masu dauke da kwayar cutar, kuma mafi yawan wadanda suka fi mutuwa a duniya sakamakon ciwon hanta. A kasar Sin kadai, an sami mutuwar sama da mutane 260,000 da cutar hanta ta hanta B da C a shekarar 2016, wanda ya kai kashi daya bisa uku na mutuwar cutar kansar hanta a duniya. A cikin 2016, cutar hanta ta C ta haifar da mutuwar mutane 160,000 daga ciwon hanta. Amurka ce ta daya a cikin kasashe uku na farko, sai Japan da China. Hepatitis C yana da ingantaccen magani wanda zai iya hana ci gaban ciwon hanta. Binciken ya kuma gano cewa cutar hanta ta hanta ta haifar da mutuwar mutane 350,000 daga cutar kansar hanta, inda China da Indiya ke da kashi 80%. Idan an yi wa mutane allurar rigakafin cutar hanta ta B bayan haihuwa, ana iya hana mafi yawan waɗannan mutuwar. A yau, kashi 52 cikin XNUMX na ƙasashe ne kawai ke ba da rigakafin cutar hanta ga jarirai. Mutane da yawa ba su san alaƙar da ke tsakanin mutuwar cutar kansar hanta da ƙaruwar ƙwayar cutar hanta ta B da C ba. Ana samun karuwar mace-mace daga ƙarshe saboda ƙarancin allurar rigakafi, rashin gwajin gwaji na yau da kullun da kuma rashin samun isasshen magani mai inganci.Raquel Peck, Shugaba na Ƙungiyar Hanta ta Duniya, ya ce: Kafin ranar cutar kansa ta duniya, muna buƙatar a gwada mutane game da cutar hanta ta hepatitis B. C, domin wannan shine matakin farko na rigakafin. Za mu iya dakatar da kai hare-hare tare. https://medicalxpress.com/news/2018-02-deaths-liver-cancer-1990s-figures.html

Biyan kuɗi zuwa ga Newsletter

Sami sabuntawa kuma kada ku rasa bulogi daga Cancerfax

Toarin Don Bincika

Lutetium Lu 177 dotatate an amince da shi ta USFDA don marasa lafiya na yara masu shekaru 12 da haihuwa tare da GEP-NETS
Cancer

Lutetium Lu 177 dotatate an amince da shi ta USFDA don marasa lafiya na yara masu shekaru 12 da haihuwa tare da GEP-NETS

Lutetium Lu 177 dotatate, magani mai ban sha'awa, kwanan nan ya sami izini daga Hukumar Abinci da Magunguna ta Amurka (FDA) ga marasa lafiya na yara, wanda ke nuna gagarumin ci gaba a cikin ilimin cututtukan cututtukan yara. Wannan amincewar tana wakiltar alamar bege ga yara masu fama da ciwace-ciwacen ƙwayoyin cuta na neuroendocrine (NETs), nau'in ciwon daji da ba kasafai ba amma ƙalubale wanda galibi ke tabbatar da juriya ga hanyoyin warkewa na al'ada.

USFDA ta amince da Nogapendekin alfa inbakicept-pmln don cutar kansar mafitsara mara tsoka da BCG.
Ciwon daji na bladder

USFDA ta amince da Nogapendekin alfa inbakicept-pmln don cutar kansar mafitsara mara tsoka da BCG.

“Nogapendekin Alfa Inbakicept-PMLN, wani labari na rigakafi, yana nuna alƙawarin magance cutar kansar mafitsara idan aka haɗa shi da maganin BCG. Wannan sabuwar dabarar ta shafi takamaiman alamomin cutar kansa yayin da ake ba da amsa ga tsarin rigakafi, yana haɓaka ingancin jiyya na gargajiya kamar BCG. Gwajin gwaje-gwaje na asibiti suna bayyana sakamako masu ƙarfafawa, yana nuna ingantattun sakamakon haƙuri da yuwuwar ci gaba a cikin sarrafa kansar mafitsara. Haɗin kai tsakanin Nogapendekin Alfa Inbakicept-PMLN da BCG yana sanar da sabon zamani a cikin maganin cutar kansar mafitsara."

Ana buƙatar taimako? Ourungiyarmu a shirye take don taimaka muku.

Muna fatan samun lafiya cikin sauri na masoyinku da na kusa.

Fara hira
Muna Kan layi! Yi Taɗi da Mu!
Duba lambar
Hello,

Barka da zuwa CancerFax!

CancerFax wani dandali ne na majagaba wanda aka keɓe don haɗa mutane da ke fuskantar ciwon daji na zamani tare da hanyoyin kwantar da hankali kamar CAR T-Cell far, TIL far, da gwaji na asibiti a duk duniya.

Bari mu san abin da za mu iya yi muku.

1) Maganin ciwon daji a kasashen waje?
2) CAR T-Cell far
3) rigakafin cutar daji
4) Shawarar bidiyo ta kan layi
5) Maganin Proton